Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
50 participants
INTERVENTIONAL
2011-10-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of 9cUAB30 in Healthy Participants
NCT00896974
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
NCT02857868
Pharmacokinetics of Mycophenolate Mofetil in Healthy Volunteers
NCT00128947
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528
Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers
NCT02258971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. The primary objective is to determine the toxicities and recommended phase II dose of 9cUAB30. The co- primary objective is to characterize the urine and plasma single dose and steady state pharmacokinetics of 9cUAB30 in normal volunteers.
SECONDARY OBJECTIVES:
I. To correlate the pharmacokinetics of 9cUAB30 with toxicity. II. To compare observed toxicity between placebo controls and each dose level. III. To assess for any change in single dose PK after repeat dosing (Day 1 vs. Day 36).
IV. To assess the following potential biomarkers of UAB30:
* Telomerase activity (measurement of telomeric repeats) in PBMCs.
* Gene expression of DNA methyltransferase in PBMCs.
* Gene expression of CYP2B6 in PBMCs.
OUTLINE: This is a dose-escalation study. Participants are randomized to 1 of 2 treatment arms.
ARM I: Participants receive retinoid 9cUAB30\* orally (PO) on days 1-28.
ARM II: Participants receive placebo\* PO on days 1-28.
Courses repeat every 28 days in the absence of unacceptable toxicity.
\*NOTE: Participants receive doses on days 8, 15, 22 and 29 after they have fasted for 12 hours.
After completion of study treatment, patients are followed up on days 7 and 30.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (retinoid 9cUAB30)
Participants receive retinoid 9cUAB30\* PO on days 1-28.
retinoid 9cUAB30
Given PO
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
cancer prevention
Disease prevention
Arm II (placebo)
Participants receive placebo\* PO on days 1-28.
placebo
Given PO
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
cancer prevention
Disease prevention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
retinoid 9cUAB30
Given PO
placebo
Given PO
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies
cancer prevention
Disease prevention
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WBC \>= 3000/mm\^3
* Platelets \>= 100,000mm\^3
* Bilirubin =\< upper limit of institutional normal
* AST =\< upper limit of institutional normal
* Creatinine within institutional normal limits
* Sodium =\< upper limit of institutional normal
* Potassium =\< upper limit of institutional normal
* Chloride =\< upper limit of institutional normal
* Bicarbonate =\< upper limit of institutional normal
* Fasting triglycerides =\<1.5 x ULN
* Fasting cholesterol =\< 1.5 x ULN
* Participants must agree to discontinue all vitamin supplements while taking study medication and for thirty days past the last dose of study medication
* The effects of 9cUAB30 on the developing human fetus are unknown; for this reason, women must agree to use TWO effective forms of birth control for the duration of study participation and for 30 days following the last dose of study medication
* The following persons are not considered to be able to father or bear children and therefore are eligible to participate without the use of concurrent birth control:
* Female with bilateral oophorectomy and/or hysterectomy
* Female with fallopian tubes cut, tied, or sealed
* Female with sterilization implant (e.g. Adiana, Essure) placed \> 3 months prior to randomization
* Female post-menopausal (\> 1 year since last menses)
* Male with vasectomy \> 3 months prior to randomization
* One of the following methods of birth control must be used by women of childbearing potential:
* Combined oral contraceptive pill in continuous use for \> 30 days prior to study entry
* Vaginal ring (e.g. NuvaRing) in continuous use for \> 30 days prior to study entry
* Skin patch (e.g. Ortho Evra) in continuous use for \> 30 days prior to study entry
* Injection (e.g. Depo-Provera, Noristerat®) in continuous use for \> 30 days prior to study entry
* Copper IUD (e.g. ParaGard)
* Note: because of the decreased effectiveness of low dose progesterone-only contraceptive methods when used with retinoids, the following hormonal methods are NOT acceptable:
* Low dose progesterone only oral contraceptive pill ("mini pills" e.g. Micronor®, Nor-Q.D., Ovrette)
* Norplant subdermal implant
* Mirena® Hormonal Implanted Uterine Device (IUD)
* In addition to the above method of contraception, one of the following methods of contraception will ALSO be used for the duration of study participation and for 30 days following the last dose of study medication:
* Diaphragm, cervical cap, or cervical shield with spermicide
* Contraceptive sponge (e.g. Today Sponge)
* Condom (male or female type) plus spermicide
* Females of child-bearing potential must have a negative pregnancy test within the current menstrual cycle and within 7 days before starting drug
* Participants must have the ability to understand, and the willingness to sign, a written informed consent document
Exclusion Criteria
* Participants may not be taking lipid lowering agents
* Participants may not be receiving any other investigational agents
* Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoids
* Participants with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 9cUAB30, breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30
* Individuals known to be HIV-positive may not participate in this study; the uncertain immune status of HIV-positive people and the potential risks of taking part in this study are too great to justify this non-treatment therapy
* Individuals with a history of cancer diagnosis or reoccurrence \< 5 years from study entry may not participate; however, individuals with a history of squamous or basal cell carcinoma of the skin \< 5 years from study entry will not be excluded from this study; the effects of this study agent on the immune system of people at risk for recurring cancer are unknown
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jill Kolesar
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO10311
Identifier Type: -
Identifier Source: secondary_id
NCI-2013-00468
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.